GlassScriptPhysician profile
Geneva D Acuff
NPI 1497327936
$9,173.74
in general payments reported to CMS, 2019-2025
23 companies · $3,590 in 2025
The $3,590 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $1,773 · 2023: $1,480 · 2024: $2,029 · 2025: $3,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,937 · Consulting Fee: $900 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,937.24 |
| Consulting Fee | $900.00 |
| Education | $261.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,345.74 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $1,021.78 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $930.46 | 2022-2025 | |
| Abbvie INC. | $906.18 | 2022-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $753.75 | 2022-2025 | Sotyktu |
| Ucb, INC. | $688.24 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $637.52 | 2021-2025 | Dupixent |
| Genzyme Corporation | $579.14 | 2022-2025 | |
| Lilly USA, LLC | $567.66 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $418.22 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $168.18 | 2022-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $160.87 | 2023-2025 | Ycanth |
| Journey Medical Corporation | $134.55 | 2022 | |
| Leo Pharma INC. | $127.08 | 2022-2025 | Anzupgo, Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.66 | 2021-2025 | Cabtreo, Jublia, Siliq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $119.05 | 2021-2025 | |
| Organon LLC | $101.39 | 2025 | Vtama |
| Regeneron Pharmaceuticals, INC. | $99.99 | 2021 | |
| Pfizer INC. | $96.74 | 2021-2025 | |
| Almirall LLC | $78.46 | 2021-2025 | Klisyri |
| Epi Health, LLC | $61.94 | 2021-2022 | |
| Dermavant Sciences, INC. | $39.36 | 2024 | Vtama |
| Sebela Pharmaceuticals INC. | $15.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geneva Acuff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.